Biomotion Sciences (SLXN) Income Statement
SLXN 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsSLXN revenue and net income
SLXN growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
SLXN quarterly EPS vs estimates
Biomotion Sciences beat the analyst EPS estimate in 2 of the last 6 quarters. Next report: November 11, 2026.
SLXN income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $14,000 | $25,000 | — | — | — | — |
| Gross profit | −$14,000 | −$25,000 | — | — | — | — |
| Research & development | $7.1M | $5.8M | $3.7M | $3.2M | — | — |
| Sales, general & admin | $4.5M | $6.7M | $928,000 | $577,000 | — | — |
| Total operating expenses | −$11.6M | $12.6M | $4.7M | $3.9M | $943,933 | $195,860 |
| Operating income | $11.6M | −$12.6M | −$4.7M | −$3.9M | −$943,933 | −$195,860 |
| Interest income | $142,000 | $1,000 | $153,000 | $114,000 | — | — |
| Interest expense | $13,000 | $52,000 | $9,000 | $85,000 | — | — |
| Income before taxes | −$11.9M | −$16.5M | −$5.1M | −$3.5M | −$755,218 | −$195,860 |
| Income taxes | $3,000 | $10,000 | $32,000 | $24,000 | — | — |
| Net income | −$11.9M | −$16.4M | −$4.9M | −$3.2M | −$755,218 | −$195,860 |
| EBITDA | −$11.9M | −$16.5M | −$5.0M | −$3.3M | −$755,000 | −$195,860 |
| EPS (diluted) | −$33.38 | −$5854.58 | −$0.41 | $0.42 | −$0.06 | −$17.81 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $3,000 | $2,000 | $3,000 | $4,000 | $3,000 | $4,000 | — | $22,000 | $7,000 | — | — | — |
| Gross profit | −$3,000 | −$2,000 | −$3,000 | −$4,000 | −$3,000 | −$4,000 | — | −$22,000 | −$7,000 | — | — | — |
| Research & development | $2.2M | $1.4M | $3.4M | $2.2M | $1.0M | $590,000 | $871,000 | $3.2M | $766,000 | $961,000 | $1.3M | $535,000 |
| Sales, general & admin | $1.5M | $1.4M | $1.0M | $1.1M | $1.3M | $1.1M | $1.0M | $4.8M | $619,000 | $281,000 | $465,000 | $186,000 |
| Total operating expenses | $3.7M | $2.7M | −$18.9M | $3.3M | $2.3M | $1.6M | $1.9M | $8.0M | $1.4M | $1.2M | $1.7M | $731,000 |
| Operating income | −$3.7M | −$2.7M | $18.9M | −$3.3M | −$2.3M | −$1.6M | −$1.9M | −$8.0M | −$1.4M | −$1.2M | −$1.7M | −$731,000 |
| Interest income | $14,000 | $32,000 | $69,000 | $39,000 | $43,000 | — | $24,000 | $0 | $6,000 | $19,000 | $33,000 | $42,000 |
| Interest expense | — | — | $6,000 | $4,000 | $0 | $9,000 | — | $52,000 | $2,000 | — | $43,000 | — |
| Income before taxes | −$3.6M | −$2.7M | −$4.4M | −$3.3M | −$2.5M | −$1.7M | −$1.7M | −$11.9M | −$1.5M | −$1.4M | −$1.7M | −$803,000 |
| Income taxes | — | — | — | — | $3,000 | — | $1,000 | $2,000 | $2,000 | $5,000 | $6,000 | $6,000 |
| Net income | −$3.6M | −$2.7M | −$4.4M | −$3.3M | −$2.5M | −$1.7M | −$1.7M | −$11.9M | −$1.5M | −$1.4M | −$1.7M | −$787,000 |
| EBITDA | −$3.7M | −$2.7M | −$4.4M | −$3.3M | −$2.5M | −$1.7M | −$5.8M | −$11.8M | −$1.5M | −$1.4M | −$1.7M | −$793,000 |
| EPS (diluted) | −$5.17 | −$8.50 | — | −$28.80 | −$4.32 | −$0.26 | −$3114.00 | −$2740.50 | −$0.03 | −$0.05 | −$10.02 | $2.01 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in SLXN's financial statements (latest annual report filed March 17, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
SLXN financial results
Biomotion Sciences reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $11.9 million. Diluted earnings per share came to −$33.38.
See the SLXN stock overview for the latest quote and news, or the SLXN chart for price history and technical indicators.
SLXN income statement FAQ
Does Biomotion Sciences have revenue?
Biomotion Sciences reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Biomotion Sciences profitable?
No. Biomotion Sciences reported a net loss of $11.9 million in fiscal 2025.
How much does Biomotion Sciences spend on research and development?
Biomotion Sciences spent $7.1 million on research and development in fiscal 2025.
What are Biomotion Sciences's earnings per share?
Biomotion Sciences earned $-33.38 per diluted share in fiscal 2025, compared with $-5854.58 a year earlier.
When will Biomotion Sciences report its next earnings?
Biomotion Sciences is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
When does Biomotion Sciences's fiscal year end?
Biomotion Sciences's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 17, 2026.